An “anemia control model” (ACM) was recently constructed and used to support the dosing of darbepoetin, an erythropoietin-stimulating agent (ESA), in patients with anemia and end-stage kidney disease who require hemodialysis (Barbieri et al., 2015; Barbieri et al., 2016). This evidence concerns the gene EPO and anemia.